Cancer Immunotherapy Market Trends Are Creating New Opportunities For Industry Leaders
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Cancer Immunotherapy Market Revenue Growth Supported By A CAGR Of 210.38% Through 2030
The cancer immunotherapy market has experienced significant expansion in recent years. Projected to rise from $124.09 billion in 2025 to $137.99 billion in 2026, this growth reflects a compound annual growth rate (CAGR) of 11.2%. Historical progress has been driven by advances in tumor immunology, a growing worldwide cancer burden, the initial achievements of monoclonal antibodies, heightened investment in oncology research and development, and the regulatory clearance of checkpoint inhibitors.
The cancer immunotherapy sector is projected to experience substantial growth over the coming years, with its value anticipated to reach $210.39 billion by 2030, driven by a compound annual growth rate (CAGR) of 11.1%. This expansion during the forecast period is fueled by several key factors, such as the increasing implementation of CAR T-cell therapies, the broadening application of these treatments into solid tumor indications, heightened financial commitments directed toward cancer vaccine development, a growing demand for targeted combination therapeutic approaches, and the establishment of favorable reimbursement policies specifically designed to support immunotherapy modalities. Significant trends shaping this forward-looking landscape include the widespread adoption of immune checkpoint inhibitors, the escalating utilization of diverse combination immunotherapy regimens, the broadened deployment of cell-based therapeutic strategies, an intensified emphasis on delivering personalized immunotherapy solutions, and a notable increase in the volume of oncology-focused clinical trials being conducted.
Download A Free Sample Report For Comprehensive Market Insights:
Cancer Immunotherapy Market Growth Drivers: What Factors Are Accelerating Expansion?
An anticipated rise in the number of cancer cases is set to drive growth in the market for cancer immunotherapies. Globally, cancer incidence is being fueled by factors such as tobacco use, alcohol consumption, obesity, sedentary habits, and environmental influences. This uptick is expected to heighten the demand for cancer immunotherapies, as patients increasingly turn to treatments that offer better recovery rates and reduced discomfort. To illustrate, projections from Cancer Research UK—a British cancer charity—released in July 2024 indicate that cancer incidence rates in the UK are likely to rise for most types between 2023-2025 and 2038-2040, with increases varying from under 1% for breast cancer to 50% for eye cancer, while a few cancers are predicted to drop, such as a 2% decline in lung cancer and a 27% fall in mesothelioma. Consequently, this growing incidence of cancer is poised to boost the need for cancer immunotherapies throughout the forecast period.
Cancer Immunotherapy Market Categorization By Product Type And Application
The cancer immunotherapy market covered in this report is segmented –
1) By Product: Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy
2) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Multiple Myeloma
3) By End User: Hospitals, Cancer Research Centers, Clinics
Subsegments:
1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies
2) By Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors
3) By Immunomodulators: Cytokines, Oncolytic Viruses, Toll-Like Receptor (TLR) Agonists
4) By Vaccines: Therapeutic Cancer Vaccines
5) By Cell Therapy: CAR T-Cell Therapy, TCR Therapy, Natural Killer (NK) Cell Therapy
Cancer Immunotherapy Market Trends: What Is Shaping Future Industry Growth?
Major players within the cancer immunotherapy sector are concentrating on creating cutting-edge solutions, including PD-1 immunotherapies, to improve access to sophisticated immune-based treatments for patients with difficult-to-treat cancers. A PD-1 immunotherapy represents a treatment aimed at immune checkpoint pathways, crafted to stimulate antitumor immune responses by hindering programmed death-1 pathway interactions. For example, in August 2025, Intas Pharmaceuticals, an India-based firm specializing in oncology and biologics, introduced HETRONIFLY (Serplulimab). This therapy stands as the first programmed death-1 inhibitor authorized globally for extensive-stage small cell lung cancer, employing a dual mechanism that targets PD-L1 and PD-L2 while relying on strong receptor internalization to boost immune engagement. Its demonstrated survival advantages—combined with a noticeably lower cost compared to existing immunotherapies—highlight its clinical significance and expand patient access to advanced cancer care within India.
Cancer Immunotherapy Market Company Landscape And Strategic Competition
Major companies operating in the cancer immunotherapy market are Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Bayer AG, Eli Lilly and Company, Adaptive Biotechnologies Corp., Argos Therapeutics Inc., Bristol-Myers Squibb Company, Cell Medica Limited, Cellular Biomedicine Group Inc., Gilead Sciences Inc., Gradalis Inc., Immatics Biotechnologies GmbH, Iovance Biotherapeutics Inc., Juno Therapeutics LLC, MacroGenics Inc., Merck & Co. Inc., Neon Therapeutics Inc., Neovii Biotech GmbH, Novartis International AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Roche Holding AG, Targovax ASA, Tessa Therapeutics Pte Ltd., TILT Biotherapeutics Ltd., Turnstone Biologics Corp., Xencor Inc., Kura Oncology Inc.
Access The Complete Cancer Immunotherapy Market Report:
Cancer Immunotherapy Market Geographic Analysis: Where Is Demand Growing The Fastest?
North America was the largest region in the cancer immunotherapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
